Diagnostic value of combined versus individual MRI parameters in distinguishing adenomatous from non-adenomatous adrenal lesions in cancer patients  by Emad-Eldin, Sally & El-Kalioubie, Mona
The Egyptian Journal of Radiology and Nuclear Medicine (2014) 45, 929–941Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLEDiagnostic value of combined versus individual
MRI parameters in distinguishing adenomatous
from non-adenomatous adrenal lesions in cancer
patients* Corresponding author. Address: Diagnostic and Intervention
Radiology Department, Cairo University Hospitals, Kasr Al-Ainy,
El-Manial, 11956 Cairo, Egypt. Tel.: +20 0106 1616935; fax: +20 02
23687673.
E-mail address: sallyemad@hotmail.com (S. Emad-Eldin).
Peer review under responsibility of Egyptian Society of Radiology and
Nuclear Medicine.
0378-603X  2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear Medicine.
http://dx.doi.org/10.1016/j.ejrnm.2014.06.004Open access under CC BY-NC-ND license.Sally Emad-Eldin *, Mona El-KalioubieDiagnostic and Intervention Radiology Department, Cairo University Hospitals, Kasr Al-Ainy, Cairo, EgyptReceived 16 May 2014; accepted 7 June 2014
Available online 4 July 2014KEYWORDS
MR;
Adrenal gland;
Adenoma;
Non-adenomatousAbstract Purpose: Our aim was to evaluate the diagnostic value of MRI using different param-
eters in differentiation of adenomas versus non-adenomas adrenal lesions.
Materials and methods: Forty-ﬁve patients with 48 adrenal masses (28 lipid rich adenomas, 3 lipid
poor adenomas, 15 metastases and 2 lymphoma) were retrospectively evaluated with MRI. The
mean diameter of adrenal mass, T2WI signal, signal drop on chemical shift imaging (CSI) and
enhancement pattern were assessed separately and in various combinations. Accuracies, sensitivi-
ties, speciﬁcities, PPV, NPV and P values by Chi-square test were calculated for individual and
combined parameters.
Results: Signal drop on CSI and enhancement pattern were the most statistically signiﬁcant diag-
nostic discriminators of adenomatous and non-adenomatous lesions with accuracies, speciﬁcities
and sensitivities of 93.8%, 90.3%, 100% and 91.7%, 93.5%, 88.2%, respectively (P-value
<0.0001). The best performance of a combination of parameters was obtained after exclusion of
the size, with an accuracy of 89.6% (P-value <0.0001).
Conclusion: The most speciﬁc predictors for adrenal mass characterization were CSI signal drop
and Gd-DTPA enhancement characteristics. Combining the MR parameters did not prove superior
930 S. Emad-Eldin, M. El-Kalioubieto those two individual parameters, however it yielded a valuable diagnostic protocol for distin-
guishing the adrenal masses, considering that size criterion should not be used as an individual dis-
criminator.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine.Open access under CC BY-NC-ND license.1. Introduction
With the increasing use of cross-sectional imaging to investi-
gate a whole host of abdominal diseases, adrenal gland abnor-
malities are being detected all the time (1). Adrenal lesions are
most commonly encountered incidentally at examinations per-
formed for other purposes (2). The adrenal gland is a relatively
frequent site for metastatic disease (3). The most common
malignant lesions that metastasize to the adrenal gland include
malignant melanoma, breast, lung, kidney, esophagus, pan-
creas, liver, stomach, and colon cancers (4–6). In patients with
a primary neoplasm, in whom an adrenal metastasis is an
important consideration, most adrenal masses are benign,
commonly non-hyper functioning adenomas (7). So accurate
characterization of these masses and proper discrimination
between adenomatous and non-adenomatous lesions are essen-
tial because the nature of the mass may have a profound effect
on patient’s care and would obviate both percutaneous biopsy
and repeated interval follow-up imaging (8).
Imaging of the adrenal gland to diagnose a mass is typically
accomplished using computed tomography (CT) or magnetic
resonance imaging (MRI) (4). CT is often considered the cor-
nerstone of adrenal imaging, being performed before and after
intravenous (iv) injection of contrast material (9). CT measures
attenuation to differentiate between benign and malignant
lesions, but the use of attenuation is not always possible
depending upon the characteristic of the lesions (10,11).
MRI of the adrenal glands can help in characterizing
lesions not properly assessed with CT. This should include
T1 and T2WI, plus chemical shift (CS) imaging which consist
of in phase (IP) and out of phase (OP) imaging. T1-fat-supres-
sion imaging before and after iv gadolinium administration is
optional. Multi-planar MRI allows precise localization and
separation of adrenal masses from the surrounding structures
(9,12).
CS MRI, being based on the principle of different reso-
nance frequency rates of protons in fat and water, has played
a role in conﬁdent differentiation of adrenal adenomas from
metastases (8). By intermittently imaging the adrenal gland
with variable T1 gradient-recalled echo (GRE) sequences,
it is possible to summate fat and water signal during in
phase sequences but null out the signal on out of phase
sequences for those voxels with equal quantities of fat and
water (9,13–15).
Although MRI with conventional sequences may be useful
in characterizing adrenal lesions, a serious limitation is the
20–30% of indeterminate lesions seen (16).
The aim of this work was to evaluate whether or not the use
of combined MRI parameters including the size, T2 signal,
CSI signal drop and the post-contrast enhancement pattern
would be more effective than the use of individual parameters
in distinguishing benign from malignant adrenal masses in can-
cer patients.2. Patients and methods
2.1. Patients
The institutional review board allowed retrospective review of
patient data sets. Among all consecutive MR abdomen studies
performed in our department from January 2012 to September
2013, we retrospectively selected patients with the following
criteria (1): patients with a known primary extra-adrenal
malignancy and adrenal masses (2). MR imaging including
T1, T2, CSI in phase/out of phase sequences as well as post
contrast sequences.
We excluded patients with inadequate follow up or patho-
logic proof of diagnosis. Also patients with adrenal cysts (diag-
nosed on MRI by water signal intensity, lack of enhancement
or signal drop, thin imperceptible walls) and pheochromocy-
toma (diagnosed on the basis of their clinical and hormonal
ﬁndings) were excluded as well.
Forty-ﬁve patients with 48 adrenal masses (2 patients with
lung cancer and 1 patient with lymphoma had bilateral lesions)
fulﬁlled these criteria and constituted our study group. They
include 18 females and 27 males). They range in age between
29 and 75 years (mean 52.67 ± 10.64).
They all had tumors of variable sites of origin, the primary
sites of tumors were lung cancer (n= 15), renal cell carcinoma
(n= 4), colonic cancer (n= 8), bladder cancer (n= 4), breast
cancer (n= 4), prostatic cancer (n= 3), gastric cancer
(n= 3), uterine cancer (n= 2), Kaposi sarcoma (n= 1), and
lymphoma (n= 1). Demographic data of the patients are pre-
sented in Table 1. The adrenal lesions were either discovered
incidentally at abdominal MR imaging done for metastatic
work-up purposes or were known to be there by previous
US or CT imaging and required further assessment for accu-
rate characterization.2.2. Imaging protocol
MR imaging was performed with a 1.5 Tesla unit (Gyroscan
Intera, Philips Medical System, Netherland) with a phased-
array body coil in the supine position. All MRI examinations
included (a) Axial SE T1WI (TR/TE 425/15 ms, matrix
204 · 256) (b) Axial and Coronal FSE T2 W (TR/TE 1800/
100 ms, matrix 204 · 256). The slice thickness of T1 and T2
sequences was 4 mm with an intersection gap of 0.4 mm.
Respiratory gating was used for SE imaging with ﬂow
compensation.
After localization imaging, CSI was performed at the level
of the adrenal mass using a T1WI Gradient Recalled Echo
(GRE) sequence with breath-holding (TR: 68–160 and TE
4.9 ms for IP images and 6.3 ms for OP images). The ﬂip
angle = 30, the matrix size = 128 · 256 and FOV varied
from 320 to 375 cm.
Table 1 Demographic data of the patients.
Age
-Range 29–75
-Mean 52.67
Number Percentage (%)
Sex
-Females 18 40
-Males 27 60
Side
-Right 24 50
-Left 18 37.8
-Bilateral 3 12.5
Primary tumor
-Lung 15 31.25
-Breast 4 8.3
-Prostate 3 6.25
-Colon 8 16.67
-Uterine 2 4.17
-Kaposi sarcoma 1 2.08
-Lymphoma 1 2.08
-Renal 4 8.3
-Gastric 3 6.25
-Bladder 4 8.3
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0.1 mmol/kg of Gadopentetate dimeglumine-DTPA (Magne-
vist; Schering, Berlin, Germany), using a dynamic technique
with preset scan times and image acquisition in the arterial
(30 s), portal (60 s) and late equilibrium phases (180–300 s).
2.3. Image analysis
The images were transferred to an independent workstation
(Philips MR extended workspace, software version 2009) and
were independently reviewed and qualitatively analyzed by
two experienced radiologists having knowledge of clinical
but no histologic information at that time.
Size was recorded with the MRI distance cursor to measure
the largest diameter in the axial plane on the unenhanced ser-
ies. Masses <4 cm were presumed to be benign while masses
>4 cm were presumed to be malignant (12).
MR signal intensity of adrenal lesions on T2WI was
described as either iso/hypointense (adenomatous lesion) or
hyperintense/heterogeneous (non adenomatous lesion) relative
to the liver parenchyma (16).
Qualitative assessment of the CS images was done with a
deﬁnite signal loss on out of phase images relative to in phase
images considered signiﬁcant for adenomatous lesions.
Absence of signal drop was considered signiﬁcant for non-ade-
nomatous lesions (16).
Homogeneous enhancement of a mass on the dynamic scan
was considered to be an indication of benignity while heteroge-
neous enhancement was considered an indicator of malignancy
(12).
The ﬁnal analysis made use of all the imaging data from the
protocol. For analysis of combined parameters the following
scoring system was used:
 Size < 4 cm: 0 / > 4 cm: 1
 T2 signal iso-hypointense: 0 / hyper-heterogeneous: 1 CSI signal drop: 0 / no signal drop: 1
 Contrast enhancement homogeneous: 0 / heterogeneous: 1
Whenever at least one parameter corresponded to a non-
adenomatous lesion, the combination of parameters and hence
their score was considered in favor of an adrenal non-ade-
nomatous lesion rather than an adenomatous one. At follow-
up imaging, 6 months of stability was considered an indicator
of benignity. On the other hand increased size of the lesion or
development of a new adrenal lesion/s was considered to be
indicative of malignancy.
Our reference standards included pathologic proof of diag-
nosis in 17 lesions including histopathology after adrenalec-
tomy and biopsy, clinical and imaging follow up (at least
6 months) in 31 lesions.
2.4. Statistical analysis
Statistical analysis was performed with SPSS (Statistical Pack-
age for the Social Sciences) V21. Results of the qualitative
analysis of MR images were classiﬁed as true positive, true
negative, false positive and false negative for the diagnosis of
adenoma. These results were entered into an excel worksheet.
Sensitivities, speciﬁcities, positive predictive values (PPV), neg-
ative predictive values (NPV), accuracies, were calculated for
individual MR parameters then for the combined parameters
used for the differentiation of adenomatous and non-ade-
nomatous adrenal masses. The P values by Chi-square test
were determined: >0.05 = non-signiﬁcant, <0.05 = signiﬁ-
cant and <0.01 = highly signiﬁcant.
3. Results
The ﬁnal diagnosis of the 48 adrenal lesions included 31
(64.6%) adenomatous benign lesions (28 lipid rich (58.4%), 3
lipid poor adenomas (6.2%) and 17 (35.4%) non adenomatous
malignant lesions (2 lymphoma and 15 metastases).
Characteristic individual MR imaging features of the adre-
nal masses including the size, the T2 signal intensity, the signal
drop on CSI and the post-contrast pattern of enhancement
used for the differentiation of adenomatous and non-ade-
nomatous malignant adrenal masses are presented in Table 2.
The sensitivity, speciﬁcity, PPV, NPV, and accuracy as well as
P-values of the individual and combined CT parameters are
presented in Table 3.
3.1. Size
All 31 adenomatous lesions ranged in sizes from 1 to 11 cm in
maximum transverse diameter (mean 4.39 ± 3.01), whereas
non-adenomatous lesions ranged in sizes from 2 to 10 cm in
maximum transverse diameter (mean 5.86 ± 2.55).
Twenty-nine adenomas were <4 cm in maximum trans-
verse diameter (94%), among which 27 were lipid rich
(Fig. 1), while 2 only were lipid poor (Fig. 2).
Two adenomas were >4 cm in maximum transverse diam-
eter (6%), including 1 lipid rich and 1 lipid poor. The lipid rich
adenoma showed isointense T2 signal, signal drop on CSI
together with homogeneous enhancement and it was stable
on follow-up. The lipid poor adenoma showed hyperintense
T2 signal, no signal drop on CSI and heterogeneous
Table 2 Individual and combined MRI parameters for
differentiation of adenomatous and non-adenomatous lesions
in cancer patients.
MRI parameter Type of lesion
Adenoma Non-Adenoma
Number % Number %
Size
<4 cm 29 94 5 29.4
>4 cm 2 6 12 70.6
T2 signal
Iso, hypo 28 93.3 2 16.7
Hyper, heterogeneous 3 6.7 15 83.3
In phase/out phase
Signal drop 28 90.3 0 0
No drop 3 9.7 17 100
Contrast enhancement
Homogenous 29 93.5 2 11.8
Heterogeneous 2 6.5 15 88.2
932 S. Emad-Eldin, M. El-Kalioubieenhancement. Diagnosis was conﬁrmed by histopathology
after adrenalectomy (Fig. 3).
Twelve non-adenomatous lesions (70.6%) were >4 cm in
maximum transverse diameter while 5 lesions (29.4%) were
<4 cm in maximum diameter (Fig. 4). Three out of these 5
lesions presented with typical malignant features namely
hyperintense/heterogeneous T2 signal, no signal drop on CSI
and heterogeneous enhancement. Whereas 2 lesions presented
overlapping features with benignity including hypointense T2
signal and homogeneous contrast, yet with no signal drop on
CSI. All these 5 lesions were proved to be malignant by
histopathology.
The size criterion was accurate in the differentiation of ade-
nomatous and non-adenomatous adrenal lesions in 41/48
masses (85.4%). This was the lowest accuracy among evalu-
ated parameters. The size criterion showed the highest sensitiv-
ity (93.5%), lowest speciﬁcity (70.6%), and lowest Chi square
value (21.9) but was statistically signiﬁcant.
3.2. T2 signal intensity
Among 31 adenomatous lesions, 28 (93.3%) showed iso/hypo-
intense T2 signal intensity while 3 lesions (6.7%) showed
hyper/heterogeneous signal. The lipid rich adenomas presented
with iso/hypointense T2 signal, except for 2 lesions, which pre-
sented with hyperintense signal and a mixture of hypo and
hyperintense signals (Fig. 5). The ﬁrst lesion had other criteriaTable 3 Statistical assessment of the MRI parameters used in diffe
MRI parameters Accuracy (%) Sensitivity (%) Spec
Size 85.4 93.5 70.6
T2 signal intensity 89.6 90.3 88.2
Signal drop 93.8 90.3 100
Enhancement 91.7 93.5 88.2
All parameters 87.5 80.6 100
All excluding signal drop 85.4 83.9 88.2
All excluding the size 89.6 83.9 100favoring the diagnosis of adenoma such as size <4 cm, signal
drop on CSI and homogeneous enhancement, and it was stable
on follow-up. The other one was also <4 cm, with signal drop
on CSI, yet it showed heterogeneous enhancement, it was sta-
ble on follow up images.
Two out of 3 lipid poor adenomas showed isointense T2
signal while the third one showed hyperintense signal. This
lesion with hyperintense T2 signal also had features suggesting
non-adenomatous etiology such as size >4 cm, no signal drop
on CSI and heterogeneous pattern of enhancement. Its ﬁnal
diagnosis was established via histopathology.
Fifteen (83.3%) out of 17 non-adenomatous malignant
lesions showed hyper/heterogeneous T2 signal, whereas 2
lesions (16.7%) showed hypointense T2 signal. These 2 lesions
had overlapping benign features such as a diameter <4 cm
and a homogeneous enhancement (Fig. 6). However both
showed no signal drop on CSI. They were concluded deﬁnitely
malignant by histopathological assessment.
T2 signal intensity was accurate in the differentiation of
adenomatous and non-adenomatous adrenal lesions in 43/48
masses (89.6%). Its accuracy was greater than the size param-
eter; the Chi square value (28.9) was also higher and statisti-
cally signiﬁcant.
3.3. CSI signal drop on out of phase compared to in phase
images
Twenty eight (90.3%) out of 31 adenomatous lesions, showed
signiﬁcant signal drop on CSI, whereas 3 (9.7%) showed no
signal drop. Those 3 lesions were diagnosed as lipid-poor
adenomas; diagnosis was conﬁrmed by histopathology in 2
of these lesions, while the remaining one showed stability on
follow-up imaging.
All 17 non-adenomatous lesion (metastases and lymphoma)
showed no signal drop on CSI (100%).
CSI signal drop was accurate in the differentiation of
adenomatous and non-adenomatous adrenal lesions in 45/48
masses (93.8%). This was the highest accuracy between evalu-
ated individual as well as combined parameters. It also showed
the highest speciﬁcity (100%), a PPV of 100%, as well as the
highest Chi square value (36.9) and was statistically signiﬁcant.
3.4. Post-contrast enhancement pattern
Twenty nine (93.5%) out of 31 adenomatous lesions showed a
homogeneous pattern of enhancement while 2 lesions (11.8%)
showed heterogeneous enhancement, 1 lipid rich and 1 lipid
poor. Both were stable on follow-up imaging and conﬁrmed
to be adenoma by histopathology.rentiation of benign and malignant adrenal masses.
iﬁcity (%) PPV (%) NPV (%) Chi square P value
85.3 85.7 21.9 <0.0001
93.3 83.3 28.9 <0.0001
100 85 36.9 <0.0001
93.5 88.2 32.1 <0.0001
100 73.9 28.6 <0.0001
92.9 75 23.5 <0.0001
100 77.3 31.1 <0.0001
Fig. 1 Lipid rich adenoma: 45-year-old female patient with history of uterine carcinoma and right adrenal lesion 2 cm in diameter. (a)
Axial T2WI image shows homogenous isointense signal of the adrenal lesion. (b) Axial T1 IP and (c) OP MR images show uniform
signiﬁcant drop of signal. Follow-up CT done a year later showed stability of the lesion.
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nomatous malignant lesions presented a heterogeneous pattern
of enhancement (Fig. 7), whereas 2 lesions (11.8%) enhanced
homogeneously. Despite presenting with a size <4 cm and
hypointense T2 signal, these 2 lesions showed no signal drop
on CSI and were conﬁrmed malignant by histopathology.
The post-contrast enhancement pattern was accurate in the
differentiation of adenomatous and non-adenomatous adrenal
lesions in 44/48 masses (91.7%). It also had the highest sensi-
tivity along with the size parameter (93.5%) and was statisti-
cally signiﬁcant.
3.5. Combined MRI patterns
The combined MR parameters succeeded in diagnosing 42
(87.5%) of the total 48 cases (89.2% of the lipid rich adeno-
mas, 0% of lipid poor adenomas and 100% of malignant
masses). Six out of 48 masses (12.5%) were misdiagnosed: 3
lipid poor and 3 lipid rich adenomas equivalent to 6 of 31
benign adenomatous masses and 0 case of the 17 malignant
non-adenomatous masses. Combined parameters showed a
100% speciﬁcity, a Chi square value of 28.6 and was statisti-
cally signiﬁcant.
When we excluded CSI from our statistical evaluation
of combined parameters, we obtained the lowest accuracy(similar to that of the size), with Chi square value dropped
to 23.5 (compared to 28.6 for combined parameters), yet it
was still statistically signiﬁcant.
The accuracies of combined MR parameters before and
after exclusion of the size parameter were 87.5% and 89.6%,
respectively. After size exclusion the Chi square value was high
31.1 and statistically signiﬁcant.
The size had the lowest accuracy and Chi square statistical
diagnostic values, while the CSI signal drop had the highest
ones obtained among the studied MR parameters. The
enhancement pattern was then closely following the CSI signal
drop pattern as regarding its high accuracy and Chi square val-
ues. Both individually were better at diagnosis than various
combinations of the MR parameters. The accuracy and Chi
Square values of various individual and combined MR param-
eters are illustrated in Diagrams 1 and 2.4. Discussion
The adrenal gland is a common site for metastasis in patients
with cancer with the rate of metastasis being between 25% to
75% depending on the type and size of the primary tumor (5).
Characterizing adrenal masses is important because the nature
of the mass may have a profound effect on patient’s care (9).
Fig. 2 Lipid poor adenoma: 55-year-old male patient with history of right hemicolectomy for colonic cancer 18 months ago and left
adrenal lesion 1.2 cm in diameter. (a) Axial T2WI shows isointense signal of the adrenal lesion (b) Axial T1WI IP and (c) OP MR images
show no signiﬁcant signal drop of the lesion. (d) Axial post contrast T1WI with fat suppression shows homogenous enhancement of the
lesion. The lesion was stable during 18 months follow up period.
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with the clinical picture. For example, in patients with cancer,
up to 75% of adrenal incidentalomas are metastatic lesions but
in patients with no history of cancer two-thirds are benign (17).
However even in patients with a primary neoplasm, in whom
an adrenal metastasis is an important consideration, a lot of
adrenal masses are also benign (7). The majority of benign
lesions are adenomas, of which 80% are benign non-function-
ing adenomas (3,18). This goes in accordance with our current
study conducted on 45 patients with extra-adrenal cancer,
where 31/48 adrenal masses were diagnosed as benign ade-
nomatous lesions (64.58%), while 17 lesions (35.42%) were
diagnosed as malignant non-adenomatous lesions.
The most common malignant lesions that metastasize to the
adrenal gland include malignant melanomas, kidney, liver,
gastrointestinal, breast, colon, lung, and bronchial carcinomas
(4,5). In our study, the most common primary cancer that
metastasized to the adrenal gland was lung cancer (31.25%)
followed by colon then prostatic cancer.
MRI with its inherent tissue characterization ability can be
utilized for the assessment of adrenal masses, with several MRI
parameters proposed in this assessment (19).
In this retrospective study we used MRI to evaluate
characteristics of adrenal lesions in patients with extra-adrenal
primary tumor. We used the following individual parameters:Size, T2 signal intensity, signal drop on CSI and post contrast
enhancement pattern. Then we evaluated the discriminatory
power of combined parameters.
In this study, when using a size cut-off value of 4 cm, 41/48
masses were properly diagnosed (P< 0.0001), with the mean
axial diameter of adenomatous lesions being 4.39 ± 3.01,
whereas that of non-adenomatous lesions was 5.86 ± 2.55.
This was in concordance with the ﬁndings of Miller et al.
who reported that, the sizes of malignant adrenal lesions were
greater than those of the remaining lesions (P< 0.05) (20).
Also Sandrasegaran et al. reported the median size of malig-
nant lesions was 4.86 cm (interquartile range, 2.77–8.52 cm),
which was greater than that of benign lesions (1.98 cm,
1.58–2.58 cm, P< 0.05) (21).
Our results showed that size was the least accurate (85.4%)
of all parameters in differentiation of adrenal adenomatous
from non-adenomatous lesions. It also showed the lowest
speciﬁcity (70.6%) and lowest Chi square value (21.9). This
is comparable to previous studies where considerable overlap
in size has been demonstrated between adenomas and non-
adenomas, especially metastases (10).
The size criterion showed 98% sensitivity and 53% speciﬁc-
ity in a previous study by Kamiyama et al. (22). Similarly, it
yielded the lowest sensitivity (58.8%), speciﬁcity (72.7%) and
accuracy (66.6%) in a study done by Mohamed et al. (23).
Fig. 3 Atypical hemorrhagic lipid poor adenoma: 61-year-old female patient recently diagnosed with breast cancer and large left adrenal
mass 11 cm in diameter. (a) Coronal T1 image shows predominantly hypointense T1 signal with intralesional hemorrhagic changes of high
T1 signal (b) Coronal T2 WI images show high T2 signal with areas of low signal (c) Axial T1 WI IP and (d) OP MR images show no
signal drop. (e) Post contrast axial T1WI shows heterogeneous enhancement of the lesion. Adrenalectomy was done and pathology
revealed atypical hemorrhagic lipid poor adenoma.
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static adrenal lesions increases to 71% if the adrenal mass is
larger than 4 cm and demonstrates an increase in size on fol-
low-up imaging within 1 year (24).
In this study, most adenomatous lesions were hypo/isoin-
tense on T2WI compared to the liver whereas most non-ade-
nomatous lesions were hyperintense or heterogeneous on
T2WI. This was supported with the previous ﬁndings of Inan
and his colleagues, who reported that 64.58% of adenomas
display iso-intense T2 signal, whereas 68.75% of metastases
were clearly hyperintense on T2WI (25).
In this study T2 signal intensity was accurate in the
differentiation of adenomatous and non-adenomatous adrenal
lesions in 43/48 masses (89.6%). Its accuracy was higher than
that of the size parameter as well as its speciﬁcity (88.2%) and
Chi square value (28.9, P< 0.0001) but yielded a lower
sensitivity (90.3%). PPV and NPV were 93.3% and 83.3%,respectively. This was in agreement with a previous study
conducted by Maurea et al. who had analyzed T2 signal of
41 adrenal masses, with reported diagnostic accuracy, sensitiv-
ity, speciﬁcity, PPV and NPV of 80%, 72%, 100%, 100% and
60%, respectively (16).
The use of MRI can be problematic since the malignant and
benign lesion signal intensity overlap (4). Adrenal cortical
adenomas have homogeneous signal intensity and enhance-
ment patterns, however T1WI and T2WI signal intensity char-
acteristics of benign adrenal adenomas are not speciﬁc and
overlap signiﬁcantly with non-adenomas, especially metastases
(26). On the other hand adrenal metastases vary in size and
appearance on MRI, and they are often heterogeneous and
are usually hyperintense compared to the normal liver on
T2WI (27,28), also they may have a low T2 signal (12).
The CS MR sequence has often been described as the main-
stay MR examination for imaging of the adrenal gland. This
Fig. 4 Adrenal metastatic deposit: 48-year-old male patient with recently diagnosed nasopharyngeal carcinoma and large, rounded left
adrenal lesion 6 cm in diameter. (a) Coronal T1 WI image shows hypointense signal of the adrenal lesion (b) coronal T2WI shows
isointense signal with areas of high signal. (c) Axial IP and (d) OP MR images show no signal drop. (e) Post contrast axial T1WI image
shows heterogeneous enhancement of the lesion. Biopsy revealed metastatic disease.
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due to the high cytoplasmic lipid concentration in adenomas
(29–31). Visual analysis of signal intensity loss on OP images
is widely performed in everyday radiological practice, but in
some cases adrenal lesions demonstrate heterogeneous signal
intensity suppression which is difﬁcult to interpret (32). Atyp-
ical signal characteristics of adrenal masses on CSI may reﬂect
variable amounts and types of lipid cells (combination of lipid-
rich and lipid-poor cells) within adenomas or come from intra-
tumor lipid in malignant lesions (e.g. adrenal cortical carci-
noma or metastases from renal cell carcinoma, hepatocellular
carcinoma, or liposarcoma) (32–34).
Previous studies reported that CS MRI can characterize
some lesions as lipid rich that were identiﬁed as lipid poor ade-
nomas on unenhanced CT. This was explained by the potentialadvantages of MRI over unenhanced CT in showing the pres-
ence of microscopic fat (20,35).
In our study, CSI signal drop was accurate in the differenti-
ation of adenomatous and non-adenomatous adrenal lesions in
45/48 masses (93.8%). This was the highest accuracy between
evaluated individual as well as combined parameters. Its sensi-
tivity was 93%. It also showed the highest speciﬁcity (100%), as
well as the highest Chi square value (36.9) and was statistically
signiﬁcant. Its PPV was 100% and NPV was 85%.
Similarly in a study conducted by Maurea et al. on 41 adre-
nal masses, CSI signiﬁcantly improved characterization of
adrenal masses compared with conventional T2WI. The Diag-
nostic accuracy, sensitivity, speciﬁcity, PPV and NPV were
93%, 90% (P< 0.05 versus T2 analysis) 100%, 100% and
80% (P< 0.05 versus T2 analysis), respectively (16).
Fig. 5 Lipid-rich adenoma: 69-year-old male patient with history of Bronchogenic Carcinoma and left adrenal mass 3.8 cm in diameter.
(a) Axial T2 WI image shows predominantly low signal with intralesional areas of cystic degeneration of high signal intensity. (b) Axial T1
WI IP and (c) OP MR images show a signiﬁcant drop of signal of the lesion. The lesion was diagnosed as adenoma based on CS MRI
ﬁndings. It showed stability on follow-up US done 6 months later.
Fig. 6 Adrenal metastatic deposit: 30-year-old male patient recently diagnosed with Kaposi sarcoma and small left adrenal nodule 2 cm
in diameter. (a) Axial T2WI shows high signal of the adrenal lesion. (b) Axial T1WI in-phase and (c) OP MR images show no signal drop.
(d) Post contrast axial T1WI image shows faint homogenous enhancement of the lesion. Adrenalectomy was done and pathology revealed
metastatic disease.
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Fig. 7 Bilateral adrenal lymphoma: 55-year-old female patient recently diagnosed with lymphoma and bilateral large adrenal masses
10 cm in diameter each. (a) Axial T1 WI IP and (b) OP images show hypo-intense signal of the lesions with no signiﬁcant signal drop. (c)
Axial T2WI show faint heterogeneous high signal intensity of the lesions. (d–e) Contrast-enhanced (d) axial and (e) coronal T1WI images
show faint heterogeneous enhancement of the lesions. Note bilateral small renal lesions (arrowed).
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ducted on 182 patients with adrenal masses assessed qualita-
tively by the CSI sequence (36). Sensitivity, speciﬁcity and
accuracy values in this study were 89%, 99% and 94%, respec-
tively indicating high predictive values for the CS sequence in
the characterization of adrenal adenomas versus non-
adenomas.
In our study, CSI was not a powerful diagnostic tool for
evaluation of lipid-poor adenomas. The 3 lipid-poor adenomas
showed no signal drop on CSI. This is in agreement with previ-
ous studies that have reported that the role of MR for charac-
terizing lipid-poor adrenal masses is limited (37–39). In a
previous study by Inan et al. there were signiﬁcant signal loss
in 38/48 adenomas (79.16%), moderate signal loss in 6/48 ade-
nomas (12.5%), no remarkable signal loss in the remaining 4
(lipid-poor) (8.33%) adenomas. None of the malignant masses
showed signal loss. Quantitative analysis of CSI sequences
revealed a sensitivity of 93.5%, a speciﬁcity of 100% and aPPV of 100% for the Signal Intensity Index. Apart from the 4
lipid-poor adenomas which did not show signal loss, all adeno-
mas and malignant masses could be differentiated by CSI (25).
Metastases from hepatocellular carcinomas, renal cellcarci-
nomas, liposarcomas and, rarely, adrenocorticalcarcinomas
can contain fat, thus resulting in false-negative images (27).
In our study, no lesions with a ﬁnal diagnosis of metastases
showed signal loss in OP imaging.
The post-contrast enhancement pattern was accurate in the
differentiation of adenomatous and non-adenomatous adrenal
lesions in 44/48 masses (91.7%). It also had the highest sensi-
tivity along with the size parameter (93.5%) and closely fol-
lowed the CSI signal drop parameter as regarding its
diagnostic discriminatory power with accuracy, speciﬁcity,
PPV, NPV and Chi square values of 91.7%, 88.2%, 93.5%,
88.2% and 32.1% (P< 0.0001) respectively.
This was supported by the previous ﬁndings of Maurea
et al. who had proved that the T1 sequence after Gadolinium
Diagram 1 shows the accuracy of various individual and
combined MR parameters.
Diagram 2 shows the Chi square value for various individuals
and combined MR parameters.
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nal masses compared with conventional T2WI. The Diagnostic
accuracy, sensitivity, speciﬁcity, PPV and NPV were 93%,
90% (P< 0.05 versus T2 analysis) 100%, 100% and 80%
(P< 0.05 versus T2 analysis) respectively, similar to the values
obtained with the CSI sequence (16).
Slapa and his colleagues previously assessed the potential
role of spin-echo, CSI and gadolinium-enhanced MRI in the
differentiation of adrenal masses, they concluded that CSI
ratio and Gd-DTPA were the most speciﬁc indicators of adre-
nal mass characterization. The CSI ratio based on OP and IP
images, reﬂected lipid content in the lesion, while Gd-DTPA
dynamic studies ratios reﬂected contrast agent inﬂow and
washout in the lesion (34).
Inan et al. concluded that on visual evaluation of dynamic
MR images, contrast enhancement patterns were homoge-
neous in 75% of the adenomas, whereas all of the malignant
masses showed heterogeneous enhancement (25).
The combination of various MR parameters has previously
been suggested for increasing the diagnostic discrimination
between adenomas and non-adenomas (34). In our study we
evaluated the diagnostic value of all parameters together, then
we excluded the CS parameter and the size.
All combined MR parameters succeeded in diagnosing 42
(87.5%) of the total 48 cases (89.2% of the lipid rich adeno-
mas, 0% of lipid poor adenomas and 100% of malignantmasses). Six out of 48 masses (12.5%) were misdiagnosed: 3
lipid poor and 3 lipid rich adenomas equivalent to 6/31 benign
adenomatous masses and 0 case of the 17 malignant masses.
Therefore the accuracy of combined parameters was not the
highest in our study. Actually it was only higher than the accu-
racy of the size and the accuracy of the combined parameters
excluding CSI. Combined parameters showed a 100% speciﬁc-
ity, a Chi square value of 28.6 and was statistically signiﬁcant.
When we excluded CSI from our statistical evaluation of
combined parameters, we obtained the lowest accuracy (simi-
lar to that of the size). Chi square value dropped to 23.5 (com-
pared to 28.6 for combined parameters).
The accuracies of combined MR parameters before and
after exclusion of the size parameter were 87.5% and 89.6%,
respectively. After size exclusion the Chi square value was high
31.1 and statistically signiﬁcant. The combination with higher
statistical diagnostic values was a combination of MR param-
eters after size exclusion. This was in agreement with the pre-
vious ﬁndings of Slapa et al. who proved that the best
performance of a combination of mean tumor diameter with
single MRI signal intensity parameter was achieved in combi-
nation with CSI ratio and in combination with T2 (liver) index
for all adrenal masses (34).
This study has few limitations. First, our study was retro-
spective in nature and had a potential for sampling bias with
a relatively small number of adrenal malignancies compared
with the large number of benign lesions. A prospective study
with a larger population is required to conﬁrm our results.
The second potential limitation was the lack of histopathologic
data from all patients with lipid rich adrenal adenomas; how-
ever, the use of 6-month follow-up has been conﬁrmed to diag-
nose adenomas in multiple studies (20,37,40,41).
Finally, the absence of quantitative assessment of signal-
intensity variations on out of phase images was compared with
in phase images through calculation of the signal intensity
index of an adenoma and non-adenoma lesion. However in
general practice, the qualitative assessment of the adrenal ade-
nomas and the presence of signal loss of the mass on opposed-
phase images to deﬁne an adrenal adenoma is often used
(30,35,37).
5. Conclusion
The most speciﬁc indicators and predictors of adrenal mass
character proved to be the CSI signal drop on out of phase
images, reﬂecting lipid content in the lesion and Gd-DTPA
enhancement characteristics. Combining the MR parameters
did not prove superior to those two individual parameters,
however it yielded a valuable diagnostic protocol for distin-
guishing the nature of adrenal masses, considering that size cri-
terion should not be used as an individual discriminator.
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